Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



ELI LILLY AND COMPANY Stock Hits 18.27% Profit Target as Forecasted by QuantWave

May 03, 2023
ELI LILLY AND COMPANY (LLY) investors saw a significant gain as the stock price reached the forecasted target of 423.05 $ on May 3, 2023, following a long signal generated by QuantWave on November 28, 2022, when the price was at 357.71 $. This successful prediction resulted in a profit of 18.27%.

The achievement of this price target for ELI LILLY AND COMPANY highlights the accuracy and effectiveness of QuantWave's forecasting algorithm. The platform's ability to identify profitable opportunities in the stock market is a testament to its sophisticated analytical capabilities and the reliable signals it provides to investors.

Market analysis suggests that several factors may have contributed to the movement of ELI LILLY AND COMPANY's stock price, including positive developments in the pharmaceutical sector, company-specific news, and overall market trends. By leveraging QuantWave's insights, investors were able to capitalize on these trends and generate significant returns.

QuantWave continues to offer users access to predictions for a wide range of stocks, providing valuable opportunities for potential profits. For investors looking to enhance their understanding of the platform's investment strategy, QuantSchool offers a comprehensive professional framework for maximizing returns. QuantSchool's educational resources reveal key principles for utilizing the QuantWave forecasting system effectively and generating consistent income in the stock market.
If you want to leave a comment, then you need Login or Register





Other data for LLY

Related data

LLYAugust 12, 2025Eli Lilly and Co LLY Traded Lower in Q2 Despite Good Results  ~1 min.

Eli Lilly and Company, despite reporting good results in the second quarter of this year, saw its stock price traded lower....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Forecasted Price Target with 20.09% Profit: QuantWave Achieves Success  ~1 min.

On January 28, 2025, QuantWave, an automated forecasting platform, issued a short signal for ELI LILLY AND COMPANY stock when it was trading at 800.2 $....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Price Target, Generating 18.65% Profit for QuantWave Users  ~1 min.

ELI LILLY AND COMPANY's stock recently reached the price target forecasted by QuantWave on 2024-08-06. The forecast signal indicated a short position, with the stock priced at 786.06 $....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Short Price Target Forecast Resulting in 19.15% Profit for QuantWave Users  ~2 min.

ELI LILLY AND COMPANY (LLY) investors recently saw the stock hitting a short price target forecast set by QuantWave, resulting in a substantial profit of 19.15%....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Price Target Resulting in 19.55% Profit - QuantWave Success  ~1 min.

ELI LILLY AND COMPANY stock has successfully reached the price target as forecasted by QuantWave, resulting in a profitable 19.55% gain for investors....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits QuantWave Forecast, Delivering 19.57% Profit  ~1 min.

ELI LILLY AND COMPANY has achieved the price target forecast set by QuantWave, signaling a 19.57% profit for investors....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Forecasted Price Target with 22.51% Profit  ~1 min.

ELI LILLY AND COMPANY stock recently achieved its forecasted price target as predicted by QuantWave, a leading automated forecasting platform....


LLYAugust 7, 2025ELI LILLY AND COMPANY Hits Forecast Price Target with 22.13% Profit on QuantWave Platform  ~2 min.

ELI LILLY AND COMPANY (LLY) recently achieved the forecast price target on the QuantWave platform, resulting in a remarkable 22.13% profit for investors who followed the short signal....


LLYAugust 1, 2025Eli Lilly and Company Completes Acquisition of Verve Therapeutics, Advancing One-Time Treatments for High Cardiovascular Risk  ~1 min.

Eli Lilly and Company has announced the successful completion of its acquisition of Verve Therapeutics, a move that will help advance innovative one-time treatments for individuals with high cardiovascular risk. This strategic decision showcases the company's commitment to revolutionizing the healthcare industry and improving patient outcomes. Investors are eagerly watching as Eli Lilly continues ...


LLYJuly 20, 2025Strong Q2 Forecast for ELI LILLY AND COMPANY by J.P. Morgan  ~1 min.

According to J.P. Morgan, Eli Lilly and Company is expected to have a strong second quarter performance. The pharmaceutical giant has been receiving positive attention from investors and analysts alike....


REGNMay 9, 2025REGENERON PHARMACEUTICALS, INC. Stock Hits QuantWave's Price Target with 24.9% Profit  ~1 min.

REGENERON PHARMACEUTICALS, INC. stock has successfully reached QuantWave's forecasted price target, resulting in a profit of 24.9%. The forecast signal was issued on February 27, 2025, with a price of 700....


LLYAugust 14, 2023ELI LILLY AND COMPANY Hits Price Target Forecast with 20.96% Profit  ~2 min.

ELI LILLY AND COMPANY (LLY) recently achieved the price target forecast set by QuantWave on June 13, 2023. The stock was signaled for a long position at a price of 439.41 $....


GSKJune 2, 2025QuantWave Achieves Forecast Success with GSK PLC, Yielding 9.23% Profit  ~1 min.

QuantWave, the automated forecasting platform, recently celebrated a significant achievement in its price target forecast for GSK PLC....


VRTXJuly 9, 2025VERTEX PHARMACEUTICALS INCORPORATED Hits QuantWave Forecast Target with 7.59% Profit  ~2 min.

VERTEX PHARMACEUTICALS INCORPORATED (VRTX) has successfully reached the forecast price target set by QuantWave on June 30, 2025....


REGNOctober 13, 2022REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 22.38% Profit: QuantWave's Success  ~2 min.

On August 4, 2022, QuantWave issued a long signal for REGENERON PHARMACEUTICALS, INC. with a price target of $749.35. The stock, which was at $612....